Clinical evaluation of personalized Helicobacter pylori treatment guided by PCR detection from fecal samples: a real-world study
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1519804 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Ruolin Peng und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Feces, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Growing antibiotic resistance in Helicobacter pylori ( H. pylori ) diminishes eradication therapy effectiveness, emphasizing the need for accurate, non-invasive diagnostic techniques. This study aims to assess the clinical utility of PCR analysis of fecal samples for detecting antibiotic resistance in guiding personalized treatment for H. pylori infection.
Methods
A retrospective, observational study was conducted across 13 hospitals within Jiangsu Province. Fecal samples were analyzed using fluorescence PCR for the 23S rRNA and gyrA genes, indicating clarithromycin and levofloxacin resistance. Then, individualized eradication recommendations were proposed for the H. pylori -positive patients. A follow-up was performed one year later to evaluate the eradication outcomes in a routine medical environment, with participants having provided informed consent.
Results
A total of 387 participants completed the eradication treatment, with an overall success rate of 91.0% (352/387, 95% CI: 87.6%-93.6%). Among them, 310 individuals received a 14-day course of bismuth quadruple therapy (BQT), achieving an eradication rate of 90.0% (279/310, 95% CI: 86.1%-93.1%). 77 participants were treated with high-dose dual therapy (HDDT) for the same duration, resulting in a slightly higher eradication rate of 94.8% (73/77, 95% CI: 87.2%-98.6%), although this difference was not statistically significant ( P =0.188). No significant differences in eradication rates were observed among various BQT antibiotic combinations ( P =0.208). The eradication rates for HDDT, based on either vonoprazan or esomeprazole, were 96.8% (61/63, 95% CI: 89.0%-99.6%) and 85.7% (12/14, 95% CI: 57.2%-98.2%), respectively, without a significant difference ( P =0.304).
Conclusion
PCR detection from fecal samples targeting the resistance genes of H. pylori is effective in guiding personalized treatments, highlighting its clinical utility and potential for broader application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Gastroenterology, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, Jiangsu, China.
- Department of Gastroenterology, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian, Jiangsu, China.
- Department of Gastroenterology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China.
- Department of Gastroenterology, Changshu Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu, China.
- Department of Gastroenterology, Changzhou Traditional Chinese Medicine Hospital, Changzhou, Jiangsu, China.
Zitieren
APA
Peng, R., Zhang, Z., Yang, C., Xu, Z., Wang, J., Chen, L., Gao, S., Tao, J., Xi, M., Ye, X., Shen, L., Zhan, Q., Din, L., Wang, J., Ou, R., Cui, J., Chen, L., Xu, X., Zhang, G., …, & Zhang, Z. (2025). Clinical evaluation of personalized Helicobacter pylori treatment guided by PCR detection from fecal samples: a real-world study. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1519804
Vancouver
Peng R, Zhang Z, Yang C, Xu Z, Wang J, Chen L, et al. Clinical evaluation of personalized Helicobacter pylori treatment guided by PCR detection from fecal samples: a real-world study. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1519804
BibTeX
@article{Peng2025,
author = {Peng, Ruolin and Zhang, Zhimei and Yang, Chuchu and Xu, Zhengyuan and Wang, Jiabin and Chen, Lei and Gao, Sujun and Tao, Jian and Xi, Meijuan and Ye, Xiaofeng and Shen, Lu and Zhan, Qiang and Din, Lijia and Wang, Jun and Ou, Rong and Cui, Jianhua and Chen, Lin and Xu, Xiaodan and Zhang, Gongyu and Xu, Chunyan and Du, Jing and Chen, Guangxia and Zhao, Xinxin and Xu, Lamei and Xu, Min and Zhang, Zhenyu},
title = {Clinical evaluation of personalized Helicobacter pylori treatment guided by PCR detection from fecal samples: a real-world study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1519804}
}
EUVIMED